Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: J Allergy Clin Immunol. 2016 Sep 5;139(3):882–888.e5. doi: 10.1016/j.jaci.2016.07.030

Table 4.

Rates of Treatment Overall and during the Buildup Phase, Maintenance Phase. Percentages reflect the the proportion of events or subjects compared to the total number listed in each column.

Treatment Events requiring treatment Subjects requiring treatment
Overall (n=1077) Buildup (n=790) Maintenance (n=294) Overall (n=104) Buildup (n=104) Maintenance (n=87)
Treated 240 (22%) 127 (16%) 113 (39%) 63 (61%) 44 (42%) 36 (41%)
Antihistamines 228 (21%) 118 (15%) 110 (38%) 61 (59%) 43 (41%) 34 (39%)
Albuterol 46 (4%) 26 (3%) 20 (7%) 22 (21%) 11 (11%) 15 (17%)
Steroids 11 (1%) 3 (0.4%) 8 (3%) 7 (7%) 3 (3%) 6 (7%)
Epinephrine 18 (2%) 4 (0.5%) 14 (5%) 12 (12%) 4 (4%) 10 (11%)
ED Visit 18 (2%) 5 (0.6%) 13 (5%) 12 (12%) 5 (5%) 9 (10%)